Trump Media and Technology Group Corp vs Merck & Co., Inc. — how do they compare? Trump Media and Technology Group Corp trades at $8.12 (market cap $2.28B), while Merck & Co., Inc. trades at $146.29 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 154.1× Trump Media and Technology Group Corp's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Trump Media and Technology Group Corp for 17 Days and Merck & Co., Inc. for 98 Days on average.
| DJT | MRK | |
|---|---|---|
Market Cap | $2.28B | $351.28B |
Volume | 3,148,379 | 7,969,665 |
Sector | Media | Health |
52-Week High | $17.07 | $156.43 |
52-Week Low | $7.06 | $82.49 |
Typical Hold Time | 17 Days | 98 Days |
Enterprise Value | $2.35B | $398.04B |
Dividend Yield | — | 2.39% |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.11, down 1.34% with bearish technical signals. The company reported $3.68M revenue in 2025 but a net loss of $712M, with negative margins and cash flow challenges. Recent news highlights a proposed merger with TAE Technologies and ongoing volatility linked to political developments and strategic shifts.
Outlook remains high-risk due to persistent losses and speculative sentiment. The merger with TAE offers potential diversification into fusion energy, but profitability concerns and insider selling weigh on investor confidence. Key risks include execution hurdles and dependence on political narratives.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →